Shots:
- Syndax to receive $117M up front, $35M as an equity investment at $24.62/share representing a premium of 31% to a closing price of $18.80, $450M in regulatory, development & commercial milestone along with royalties on Ex-US sales. Both companies will take part in a 50:50 US profit share
- Incyte will lead the global commercial activities of axatilimab across all indications. Syndax holds an option to co-promote in the US
- The companies will share development costs at a rate of 55% (Incyte) & 45% (Syndax). The P-II AGAVE-201 trial results are expected in 2023 & both companies plan to expand the development of axatilimab in cGVHD with additional monothx. & combination trials in 2022
Click here to read full press release/ article | Ref: Incyte | Image: List 23
The post Incyte Enters into an Exclusive WW License Agreement with Syndax to Develop and Commercialize Axatilimab for cGVHD and Other Fibrotic Diseases first appeared on PharmaShots.
